JD Gillmore

486 total citations
37 papers, 312 citations indexed

About

JD Gillmore is a scholar working on Molecular Biology, Nephrology and Epidemiology. According to data from OpenAlex, JD Gillmore has authored 37 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 6 papers in Nephrology and 5 papers in Epidemiology. Recurrent topics in JD Gillmore's work include Amyloidosis: Diagnosis, Treatment, Outcomes (28 papers), Parathyroid Disorders and Treatments (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). JD Gillmore is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (28 papers), Parathyroid Disorders and Treatments (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). JD Gillmore collaborates with scholars based in United Kingdom, United States and Italy. JD Gillmore's co-authors include Philip N. Hawkins, Ashutosh Wechalekar, Helen J. Lachmann, Prayman Sattianayagam, Zoë Fox, Simon Gibbs, Dorota Rowczenio, Angelika F. Hahn, Jennifer H. Pinney and Arie J. Stangou and has published in prestigious journals such as Applied and Environmental Microbiology, European Heart Journal and Annals of the Rheumatic Diseases.

In The Last Decade

JD Gillmore

34 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JD Gillmore United Kingdom 7 283 90 80 52 51 37 312
Ingrid I. van Gameren Netherlands 6 295 1.0× 58 0.6× 94 1.2× 34 0.7× 66 1.3× 14 325
S. Mahmood United Kingdom 5 243 0.9× 71 0.8× 60 0.8× 62 1.2× 47 0.9× 15 287
Ketna Patel United Kingdom 7 178 0.6× 41 0.5× 62 0.8× 57 1.1× 54 1.1× 18 261
Karen Wells United States 4 332 1.2× 91 1.0× 96 1.2× 106 2.0× 77 1.5× 4 355
Dina Brauneis United States 10 281 1.0× 59 0.7× 44 0.6× 117 2.3× 64 1.3× 24 298
C. Frangié France 7 59 0.2× 29 0.3× 81 1.0× 22 0.4× 15 0.3× 9 217
Emel Gönüllü Türkiye 8 104 0.4× 46 0.5× 8 0.1× 18 0.3× 34 0.7× 37 224
Maria Eleni Drosou United States 5 156 0.6× 22 0.2× 99 1.2× 37 0.7× 12 0.2× 7 195
Georgi Manukjan Germany 11 88 0.3× 28 0.3× 14 0.2× 37 0.7× 19 0.4× 26 265
Jaime Sánchez del Pozo Spain 9 159 0.6× 25 0.3× 18 0.2× 13 0.3× 15 0.3× 27 264

Countries citing papers authored by JD Gillmore

Since Specialization
Citations

This map shows the geographic impact of JD Gillmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JD Gillmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JD Gillmore more than expected).

Fields of papers citing papers by JD Gillmore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JD Gillmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JD Gillmore. The network helps show where JD Gillmore may publish in the future.

Co-authorship network of co-authors of JD Gillmore

This figure shows the co-authorship network connecting the top 25 collaborators of JD Gillmore. A scholar is included among the top collaborators of JD Gillmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JD Gillmore. JD Gillmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sachchithanantham, Sajitha, S. Harrison, Richa Manwani, et al.. (2019). PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS. HemaSphere. 3(S1). 958–958. 2 indexed citations
2.
Kotecha, Tushar, Esteban González López, Andrej Ćorović, et al.. (2019). 549High prevalence of intracardiac thrombi in cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 20(Supplement_2). 1 indexed citations
3.
Kotecha, Tushar, Andrea Baggiano, Michele Boldrini, et al.. (2018). Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy. UCL Discovery (University College London). 1 indexed citations
5.
Jaccard, Arnaud, Raymond L. Comenzo, Parameswaran Hari, et al.. (2014). Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 99(9). 1479–1485. 85 indexed citations
6.
Dubrey, S. W., et al.. (2012). Diagnostic dilemma and sudden death outcome: a case of amyloid cardiomyopathy. Clinical Medicine. 12(6). 596–597. 2 indexed citations
7.
Gilbertson, JA, et al.. (2010). Localised amyloid at injection sites derived from porcine and human insulin. UCL Discovery (University College London). 1 indexed citations
8.
Gillmore, JD, et al.. (2010). Solid organ transplantation for non-TTR amyloidoses: consensus opinion. UCL Discovery (University College London). 1 indexed citations
9.
Gillmore, JD, Helen J. Lachmann, Thirusha Lane, et al.. (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study. UCL Discovery (University College London). 3 indexed citations
10.
Whelan, CJ, Babita Pawarova, Thirusha Lane, et al.. (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment. UCL Discovery (University College London). 1 indexed citations
11.
Gillmore, JD, Kim Cocks, Prayman Sattianayagam, et al.. (2010). UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design. UCL Discovery (University College London). 2 indexed citations
12.
Harding, Stephen, Helen J. Lachmann, JD Gillmore, et al.. (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis. Clinical Genetics. 84(2). 175–82. 2 indexed citations
13.
Offer, Mark, et al.. (2006). Natural history and outcome of amyloidosis in the elderly. UCL Discovery (University College London). 1 indexed citations
14.
Lachmann, Helen J., JA Gilbertson, JD Gillmore, et al.. (2006). Characterisation of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant. UCL Discovery (University College London). 1 indexed citations
15.
Lachmann, Helen J., et al.. (2002). Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis.. UCL Discovery (University College London). 2 indexed citations
16.
Lachmann, Helen J., JD Gillmore, M B Pepys, & Philip N. Hawkins. (2002). Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy.. UCL Discovery (University College London). 3 indexed citations
17.
Lachmann, Helen J., et al.. (2002). Frequency of hereditary systemic amyloidosis masquerading as immunoglobulin light chain, AL (primary), amyloidosis.. UCL Discovery (University College London).
18.
Gillmore, JD, JF Apperley, Helen J. Lachmann, et al.. (2001). Combination chemotherapy for systemic AL amyloidosis. UCL Discovery (University College London). 1 indexed citations
19.
Gillmore, JD, S. Madhoo, Mark B. Pepys, & Philip N. Hawkins. (2000). Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy. Nuclear Medicine Communications. 21(8). 735–740. 10 indexed citations
20.
Daily, O. P., S W Joseph, JD Gillmore, Rita R. Colwell, & Ramon J. Seidler. (1981). Identification, distribution, and toxigenicity of obligate anaerobes in polluted waters. Applied and Environmental Microbiology. 41(4). 1074–1077. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026